Assisted circulation: experience with the Novacor Left Ventricular Assist System.
Surgical therapy for the treatment of heart failure is a relatively young solution to a problem that has overwhelmed civilizations dating back to the First Dynasty. Despite centuries of enormous multidisciplinary medical and technological advance, nearly 2000 people in the USA died of cardiovascular disease every day in 2006, averaging one death every 35 seconds, and claiming more lives than the next four leading causes of death combined. In 2007, one in 30 female deaths will be from breast cancer, while one in 2.6 will be from cardiovascular disease. The prevalence of heart failure in our population is a staggering 5 million in the USA and 6.5 million in Europe per year. Furthermore, based on the 44-year follow-up of the National Heart, Blood, and Lungs Institute Framingham Heart Study, 80% of men and 70% of women under the age of 65 years who have heart failure will die within 8 years. The focus of this article will be to review the history and future of the Novacor Left Ventricular Assist System as it relates to the failing heart; the story of how the innovator, the researcher, the engineer and the surgeon have come together to offer a surgical solution to a medical problem of inconceivable scope.
Farkas
Emily A
EA
St. Louis University School of Medicine, Department of Surgery, Section of Cardiothoracic Surgery, 333 Cedar Street, FMB 121, New Haven, CT 06504, USA.
Elefteriades
John A
JA
D001243:Assisted Circulation / Q000295:instrumentation*; D005260:Female; D006352:Heart Ventricles / Q000503:physiopathology*; D006353:Heart-Assist Devices / Q000266:history / Q000639:trends; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D019736:Prostheses and Implants; D020521:Stroke / Q000453:epidemiology; D016276:Ventricular Function